| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 106.51 | 158.9% |
| Total Income | 106.51 | 158.9% |
| Expenditure | 33.93 | 51.7% |
| PBT | 65.17 | 279.7% |
| Net Profit | 40.77 | 209.0% |
| OPM | 68.14% | 138.89pp |
| NPM | 38.28% | 129.15pp |
| EPS | 0.25 | 208.7% |
Ironwood Pharmaceuticals Reports Strong Q1 2026 Results
07 May 2026 · 7 May, 4:42 pm
Summary
Ironwood Pharmaceuticals reported strong financial results for the first quarter of 2026, driven by a significant increase in LINZESS U.S. net sales and prescription demand. The company achieved a GAAP net income of $41 million and adjusted EBITDA of $77 million. Ironwood is progressing with its clinical trials for apraglutide and anticipates site initiations for the Phase 3 confirmatory trial in Q2 2026. The company reaffirmed its full-year 2026 financial guidance.
Key Highlights
- 1
LINZESS U.S. net sales reached $273 million in Q1 2026, reflecting a 97% year-over-year growth.
- 2
Total revenue for Q1 2026 was $107 million.
- 3
Ironwood reported GAAP net income of $41 million and adjusted EBITDA of $77 million for Q1 2026.
- 4
LINZESS prescription demand increased by 5% year-over-year in Q1 2026, totaling 56.0 million capsules.
- 5
The company maintains its full-year 2026 financial guidance.
- 6
Net profit for the LINZESS U.S. brand collaboration was $204.7 million in Q1 2026, a 211% increase compared to Q1 2025.
Management Comments
Tom McCourt
Our first quarter of 2026 delivered strong financial performance, driven by significantly improved net price and mid-single digit prescription growth for LINZESS, positioning us well to achieve our full-year 2026 financial guidance. We expect strong first quarter revenue to result in significant operating cash flows in the second quarter of 2026, which will help support repayment of our 2026 convertible notes at maturity in June.
Michael Shetzline
We remain on track for site initiation for the confirmatory STARS-2 Phase 3 clinical trial in the second quarter. Building on the positive results from STARS, we believe that the highly potent, selective, and long-acting pharmacologic properties of apraglutide have the potential to drive best-in-class efficacy and tolerability with once-weekly dosing and redefine the standard of care in SBS-IF. Importantly, the long-term data generated to date show compelling enteral autonomy outcomes, with rapid and sustained reductions in parenteral support over time.
Informational and educational content only. Not investment advice.